Advertisement

Topics

Helsinn And MEI Pharma Announce First Patient Dosed In Pivotal Phase III Study Of Pracinostat And Azacitidine In Acute Myeloid Leukemia

20:00 EDT 1 Aug 2017 | BioSpace

  Life Sciences Jobs   ...

Original Article: Helsinn And MEI Pharma Announce First Patient Dosed In Pivotal Phase III Study Of Pracinostat And Azacitidine In Acute Myeloid Leukemia

NEXT ARTICLE

More From BioPortfolio on "Helsinn And MEI Pharma Announce First Patient Dosed In Pivotal Phase III Study Of Pracinostat And Azacitidine In Acute Myeloid Leukemia"

Quick Search
Advertisement